Maka, I agree it is an amazing situation.
OBJ has limited overheads.
A multi product platform that seems to have unlimited applications, easy to adapt into a product, with P&G in the process of using OBJ's disruptive technology across the board....who can guess how many products
At my guess GSK will not mess around with their final trials.
The OBJ technology application is not for a niche market, it for the market.
missing the forest for the trees, page-31
-
- There are more pages in this discussion • 8 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add WFL (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
0.3¢ |
Change
0.000(0.00%) |
Mkt cap ! $1.478M | |||
| Open | High | Low | Value | Volume |
| 0.0¢ | 0.0¢ | 0.0¢ | $0 | 0 |
| WFL (ASX) Chart |
Day chart unavailable